Skip to main content

Table 1 Initial clinical characteristics

From: Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy

Variables

LVRR (+)

LVRR (−)

p value

(n = 15)

(n = 29)

Age (years)

60 ± 11

58 ± 13

0.512

Men

13 (87%)

26 (89%)

0.767

New York Heart Association class

I – II

11

24

0.207

III – IV

5

5

 

Diabetes mellitus

4 (27%)

3 (10%)

0.206

Atrial fibrillation

6 (40%)

4 (14%)

0.067

Nonsustained ventricular tachycardia

6 (40%)

11 (38%)

0.894

Serum creatinine (mg/dl)

0.87 ± 0.16

0.81 ± 0.25

0.406

Estimated glomerular filtration rate (ml min-1 1.73 m-2)

80.3 ± 12.2

79.8 ± 12.1

0.738

Complete left bundle brunch brock

2 (13%)

6 (21%)

0.549

QRS duration (ms)

101 ± 14

111 ± 32

0.173

Follow-up periods (years)

5.9 ± 3.2

4.4 ± 2.8

0.220

Pharmacological treatments

β blockers

15 (100%)

29 (100%)

>0.99

Carvedilol

13 (87%)

24 (83%)

0.737

Dose (mg/day)

11.3 ± 4.8

10.8 ± 5.3

0.761

Metoprolol

2 (13%)

5 (17%)

0.735

Dose (mg/day)

60.0 ± 28.2

56.0 ± 21.9

0.879

Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers

12 / 3 (100%)

24/5 (100%)

>0.99

Enalapril

10 (67%)

20 (69%)

0.877

Dose (mg/day)

5.2 ± 1.8

4.6 ± 0.9

0.318

Losartan

2 (13%)

3 (20%)

0.767

Dose (mg/day)

37.5 ± 17.7

41.7 ± 14.4

0.738

Loop diuretics

13 (87%)

27 (93%)

0.596

Spironolactone

7 (45%)

15 (52%)

0.751

Digitalis

11 (73%)’

20 (67%)

0.763

Amiodarone

1 (7%)

4 (14%)

0.647

  1. Data are presented as mean ± SD or n (%). LVRR, left ventricular reverse remodeling.